Afghanistan vs South Africa: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Afghanistan
63.0%
in 2025
South Africa
65.0%
in 2025
Afghanistan rank
142nd
South Africa rank
140th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Afghanistan
- South Africa
How they compare
South Africa currently reports 65.0% against 63.0% in Afghanistan, a difference of 2.0%.
Across all 18 years both countries report, South Africa has been ahead every year.
Afghanistan ranks 142nd and South Africa ranks 140th of 194 countries.
South Africa has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Afghanistan | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 5.0% | 5.0% | South Africa |
| 2010s | 36.3% | 77.2% | 40.9% | South Africa |
| 2020s | 59.2% | 81.7% | 22.5% | South Africa |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Afghanistan or South Africa?
- South Africa, at 65.0% against 63.0% in Afghanistan as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Afghanistan and South Africa?
- 2.0%, with South Africa ahead.
- How many years of comparable data are there for Afghanistan and South Africa?
- 18 years are reported by both, from 2008 to 2025.
- How do Afghanistan and South Africa rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Afghanistan ranks 142nd and South Africa ranks 140th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.